Form 4: Stoke Therapeutics CMO Sells Shares Under 10b5-1 Plan

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 5,931 shares of common stock on November 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported the sale of 5,931 shares of common stock.
• The transactions occurred on November 3, 2025.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2024.
• The shares were sold at weighted average prices ranging from $25.2242 to $29.35 per share.
• Following these transactions, Barry Ticho beneficially owns 7,195 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled sale of shares by an insider under a Rule 10b5-1 plan, which is a neutral event as it indicates planned liquidity rather than a reaction to new information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on new material non-public information.

Negatives

• An officer selling a significant number of shares could be perceived negatively by investors, even if pre-planned.

Risks

• No specific risks are mentioned in the filing beyond the inherent market risk associated with stock ownership.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• No notable quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

This Form 4 filing reports a routine insider transaction, specifically the sale of shares by a Chief Medical Officer under a pre-arranged trading plan. Such transactions are common across all industries, including biotechnology, and do not inherently reflect broader industry trends unless a pattern of significant insider selling emerges across the sector.

Comparison to Industry Standards

• This filing is a standard disclosure of an insider stock transaction under SEC regulations.
• The use of a Rule 10b5-1 plan is a common practice for corporate insiders to sell shares in a pre-scheduled manner, mitigating concerns about trading on material non-public information.
• There are no specific comparable companies, projects, or results mentioned in this filing to assess against global benchmarks.

Stakeholder Impact

• Shareholders may view insider sales with scrutiny, but the disclosure of a Rule 10b5-1 plan typically mitigates concerns that the sale is based on new negative information. The impact is generally minimal for routine, pre-planned sales.

Next Steps

• No specific future actions, events, or milestones are mentioned in this filing.

Key Dates

Recommendation

This Form 4 details a pre-scheduled sale of shares by the Chief Medical Officer under a Rule 10b5-1 plan. Such transactions are typically for personal financial planning and do not inherently signal a change in the company's fundamental outlook or performance. While any insider selling can be viewed with caution, the pre-planned nature reduces its significance as an indicator of future stock performance. Therefore, a "hold" recommendation is appropriate, as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Stoke Therapeutics, STOK, Form 4, insider trading, stock sale, 10b5-1 plan, Barry Ticho, Chief Medical Officer, equity disposition